Point72 Asset Management L.P. Raises Stock Position in uniQure (NASDAQ:QURE)

Point72 Asset Management L.P. grew its stake in uniQure (NASDAQ:QURE - Free Report) by 81.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,771,352 shares of the biotechnology company's stock after acquiring an additional 794,459 shares during the period. Point72 Asset Management L.P. owned 3.63% of uniQure worth $31,282,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Twin Tree Management LP bought a new position in shares of uniQure during the fourth quarter worth approximately $77,000. ADAR1 Capital Management LLC bought a new position in shares of uniQure in the 4th quarter valued at $177,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 969 shares during the period. Wells Fargo & Company MN increased its stake in shares of uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after buying an additional 1,503 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of uniQure during the fourth quarter worth $287,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Stock Down 1.5%

Shares of uniQure stock traded down $0.23 during midday trading on Thursday, hitting $15.27. The company had a trading volume of 219,235 shares, compared to its average volume of 1,885,843. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a market capitalization of $836.43 million, a P/E ratio of -3.08 and a beta of 0.10. The company has a 50 day moving average of $12.39 and a 200 day moving average of $12.47.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $1.57 million for the quarter, compared to analysts' expectations of $5.93 million. On average, equities analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other uniQure news, CFO Christian Klemt sold 10,438 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares of the company's stock, valued at $2,240,441.70. This represents a 4.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares of the company's stock, valued at $6,703,461.66. This represents a 4.17% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,830 shares of company stock valued at $961,401. Corporate insiders own 4.74% of the company's stock.

Analyst Upgrades and Downgrades

QURE has been the topic of a number of recent research reports. Wall Street Zen upgraded uniQure to a "sell" rating in a report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Monday, April 21st. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research note on Monday. Chardan Capital reiterated a "buy" rating and issued a $38.00 price objective on shares of uniQure in a research note on Monday, May 12th. Finally, Guggenheim reissued a "buy" rating and set a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.